Work

Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.3089

Authors: Funda Meric-Bernstam, Satish Shah, Manish Sharma, Annick Metcalfe, Guylaine Roy, Lynn Marie Douglas, Christian Marsolais, Ira Seth Winer

Institutions: The University of Texas MD Anderson Cancer Center, Theratechnologies (Canada), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Nanoparticle-Based Drug Delivery

Subfield: Biomaterials

Field: Materials Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379282910

Cites:

Cited by: 5

Related to: 10